Table 2.
The clinico-pathological characteristics of 377 patients with NPC.
| Variables | Low PIV(%) | High PIV (%) | P Value |
|---|---|---|---|
| Age | |||
| ≤60 | 112 (86.8 %) | 215 (86.7 %) | 0.972 |
| ＞60 | 17 (13.2 %) | 33 (13.3 %) | |
| Gender | |||
| Male | 83 (64.3 %) | 183 (73.8 %) | 0.056 |
| Female | 46 (35.7 %) | 65 (26.2 %) | |
| ECOG PS | |||
| 0 | 91 (70.5 %) | 138 (55.6 %) | 0.017 |
| 1 | 37 (28.7 %) | 105 (42.4 %) | |
| 2 | 1 (0.8 %) | 5 (2.0 %) | |
| BMI | |||
| ＜18.5 | 10 (7.8 %) | 14 (5.6 %) | 0.545 |
| 18.5–24 | 61 (47.2 %) | 130 (52.4 %) | |
| ≥24 | 58 (45.0 %) | 104 (41.9 %) | |
| EBV-DNA | |||
| ＜400 | 78 (60.5 %) | 134 (54.0 %) | 0.274 |
| ≥400 | 51 (39.5 %) | 114 (46.0 %) | |
| T stage | |||
| 1-2 | 86 (66.7 %) | 110 (44.4 %) | ＜0.001 |
| 3-4 | 43 (33.3 %) | 138 (55.6 %) | |
| N stage | |||
| 0-1 | 31 (24.0 %) | 54 (21.8 %) | 0.697 |
| 2-3 | 98 (76.0 %) | 194 (78.2 %) | |
| Clinical stage | |||
| I-III | 106 (82.2 %) | 177 (71.4 %) | 0.024 |
| IVa | 23 (17.8 %) | 71 (28.6 %) | |
| Treatment | |||
| CCRT | 43 (33.3 %) | 78 (31.5 %) | 0.728 |
| Non-CCRT | 86 (66.7 %) | 170 (68.5 %) | |
ECOG PS Eastern Cooperative Oncology Group Performance Status, BMI Body Mass Index, CCRT concurrent chemo-radiotherapy.